Drug Type AAV based gene therapy |
Synonyms Adeno-associated vector expressing human codon-optimized guanidinoacetate N-methyltransferase under a ubiquitous-expressing promoter |
Target |
Action agonists |
Mechanism GAMT agonists(guanidinoacetate N-methyltransferase agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Guanidinoacetate Methyltransferase Deficiency | Preclinical | United States | 18 Feb 2025 |